PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Science. Author manuscript; available in PMC 2008 September 8.
Published in final edited form as:
PMCID: PMC2532521
NIHMSID: NIHMS64217

Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation

Abstract

The canonical Wnt-β-catenin signaling pathway is initiated by induction of phosphorylation of one of the Wnt receptors, low density lipoprotein receptor-related protein (LRP) 5/6, at Thr1479 and Ser1490. We identified, by screening a human kinase siRNA library, phosphatidylinositol 4-kinase type II (PI4KII) α and phosphatidylinositol-4-phosphate 5-kinase type I (PIP5KI) as required for Wnt3a-induced LRP6 phosphorylation at Ser1490 in mammalian cells and confirmed that these kinases are important for Wnt signaling in Xenopus embryos. Wnt3a stimulates the formation of phosphatidylinositol 4,5-bisphosphates [PtdIns (4,5)P2] through frizzled (Fz) and dishevelled (Dvl), the latter of which directly interacted with and activated PIP5KI. PtdIns (4,5)P2 in turn regulated phosphorylation of LRP6 at Thr1479 and Ser1490. Therefore, our study reveals a new signaling mechanism for Wnt to regulate LRP6 phosphorylation.

Members of the Wnt family of secretory glycoproteins have important roles in various physiological and pathophysiological processes, including embryonic development, bone development, neuronogenesis, adipogenesis, myogenesis, organogenesis, lipid and glucose metabolism, and tumorigenesis (1-5). Canonical Wnt binds to two receptors, LRP5/6, and Fz proteins, leading to phosphorylation of LRP6 at Thr1479 by Casein kinase (CK) 1γ and at Ser1490 by Glycogen Synthase Kinase (GSK) 3 (6-10). Wnt appears to regulate Thr1479 phosphorylation by inducing the formation of LRP6 aggregates (9), whereas it regulates Ser1490 phosphorylation through GSK in a Axin-dependent manner (10). To determine whether there are other kinases that take part in regulation of LRP6 phosphorylation, we screened a human kinase siRNA library from Applied Biosystems for effects on Wnt-induced accumulation of cytosolic β-catenin detected by an Enzyme-Linked ImmunoSorbent Assay (ELISA) and on phosphorylation of Ser1490 of LRP6 detected by protein immunoblotting in human embryonic kidney (HEK) 293T cells. Multiple phosphatidylinositol (PtdIns) kinase siRNAs inhibited cytosolic β-catenin accumulation (Fig. S1A and Table SI) and phosphorylation of LRP6 at Ser1490 (Fig. 1, A and B) in response to purified Wnt3a protein. Among the tested PtdIns kinase siRNAs, siRNAs for PI4KIIα and PIP5KIβ had the strongest inhibitory effects (Fig. S1A, and Fig. 1, A and B). These siRNA also inhibited Wnt3a-induced reporter gene activity (Fig. S1B). Additional siRNAs for both PI4KIIα and PIP5KIβ directed against different targeting sequences were also tested (Fig. S1, B and C, and Fig. 1, A and B). To further verify that the effects of these siRNAs were specific, we restored Wnt signaling by expressing the kinases knocked down by the siRNAs (Fig. S1, D to G). PI4KIIα and PIP5KIβ siRNAs did not inhibit lithium- and Axin1/2 siRNA-induced accumulation of β-catenin (Fig. S1, C and H), but β-catenin siRNA did. Thus, these siRNAs appeared to affect Wnt signaling by affecting LRP6 phosphorylation rather than Wnt signaling downstream components.

Figure 1
Effect of depletion of PtdIns kinases on Wnt3a signaling

PIP5KIγ siRNAs showed a weak effect, whereas PIP5KIα siRNAs showed little effect in HEK293T cells (Fig. 1B). However, treatment of the cells with combinations of the PIP5KI siRNAs showed that the combination targeting all three PIP5KI isoforms reduced Wnt3a-indcued accumulation of β-catenin and phosphorylation of LRP6 almost to basal levels (Fig. S1, C and I), suggesting that PIP5KIα and 1γ may also contribute to Wnt signaling in these cells.

To further investigate the involvement of PtdIns kinases in Wnt signaling, we examined whether these PtdIns kinases also functioned in Wnt signaling in Xenopus. A morpholino (MO) targeting Xenopus PI4KIIα inhibited XWnt8-induced, but not β-catenin-induced, axis duplication in Xenopus embryos (Fig. (Fig.1C1C and S2A). Although PIP5KIβ-MO showed little effect, a MO targeting its close homolog PIP5KIα inhibited XWnt8-induced, but not β-catenin-induced, axis duplication (Fig. 1D). Consistent with the phenotypes, PIP5KIα and PI4KIIα MOs reduced phosphorylation of LRP6 (Fig. S2B). In addition, expression of catalytically inactive PIP5KIα and PI4KIIα mutants suppressed axial duplication induced by XWnt8, but not β-catenin (Fig. S2C), further confirming the importance of these kinases in Wnt signaling.

Inhibition of zygotic Wnt-β-catenin signaling induces anteriorized phenotypes that include enlarged cement glands and head structures (11). PI4KIIα-MO that injected into the dorsal regions of Xenopus embryos induced strong anteriorized phenotypes in over 70% embryos. This effect could be partially reversed by coinjection of Xenopus PI4KIIα mRNA (Fig. (Fig.1E1E and S2D). Although PIP5KIα-MO had little effect on the phenotype, PIP5KIβ-MO induced anteriorized phenotypes in around 50% of treated embryos. The PIP5KIβ MO effect could be almost completely reversed by injection of XPIP5KIβ mRNA (Fig. (Fig.1E1E and S2D). These results together indicate that PtdIns kinases regulate endogenous Wnt signaling in Xenopus embryos.

Because sequential phosphorylation of PtdIns lipids by PI4KII and PIP5KI constitutes the major pathway for PtdIns (4,5)P2 production in most cells (12, 13), we suspected that PtdIns (4,5)P2 might regulate phosphorylation of Ser1490. To test this hypothesis, we delivered PtdIns plus all of the 7 possible isoforms of PtdIns Phosphates at equal molar concentrations into HEK 293T cells in a lipid carrier. PtdIns (4,5)P2 showed the strongest stimulatory effect on Wnt3a-induced phosphorylation of Ser1490 (Fig. 2A). In addition, delivery of PtdIns (4)P, but not PtdIns, rescued the effect of PI4K siRNA, whereas delivery of PtdIns (4,5)P2, but not PtdIns (4)P, rescued the effect of PIP5K siRNA on Wnt3a-induced phosphorylation of LRP6 (Fig. 2, B and C) and β-catenin accumulation (Fig. S3). These results suggest that PtdIns (4,5)P2 may be the primary PtdIns lipid involved in the regulation of Ser1490 phosphorylation.

Figure 2
Effect of PtdIns (4,5)P2 on Wnt3a signaling

To further investigate the involvement of PtdIns (4,5)P2 in regulating phosphorylation of LRP6, we used a rapidly inducible PtdIns (4,5)P2 hydrolysis system, in which rapamycin induces the heterodimerization of membrane-targeted FRP (fragment of mammalian target of rapamycin that binds FKBP) and FKBP12 (FK560-binding protein 12) fused with a truncated form of type IV phosphoinositide 5-phosphatase, leading to activation of the phosphatase (14, 15). In this system, rapamycin reduced the amount of PtdIns (4,5)P2 in cells expressing both FRP and phosphatase-fused FKBP12, but not in those expressing FRP and FKBP12 alone (Fig. 2D). Rapamycin also attenuated phosphorylation of LRP6 only in cells expressing both FRP and phosphatase-fused FKBP12 (Fig. 2E).

We next tested whether Wnt3a can stimulate PtdIns (4,5)P2 production by establishing an ELISA to determine the PtdIns (4,5)P2 contents and detected significant Wnt3a-induced stimulation of PtdIns (4,5)P2 production (more than 2-fold increases) in HEK293T, Hela, and NIH3T3 cells (Fig. S4A). We confirmed these results by High Performance Liquid Chromatography (HPLC) and Thin Layer Chromatography (TLC) (Fig. (Fig.3A,3A, and S4, B and C). Therefore, these results demonstrate that Wnt3a can induce PtdIns (4,5)P2 formation, which may regulate phosphorylation of LRP6. The findings that the PI4KIIα siRNA abolished, and the PIP5KIβ siRNA reduced, Wnt3a-induced accumulation of PtdIns (4,5)P2 (Fig. 3B) confirm the involvement of these PtdIns kinases in Wnt3a-induced formation of PtdIns (4,5)P2.

Figure 3
Stimulation of PtdIns (4,5)P2 formation by Wnt3a through Fz and Dvl

We detected expression of Fz2, 3, 4, 5, and 6 in HEK293T cells by RT-PCR and made and validated two sets of siRNAs for each of these Fz genes (Table SII). Fz5 siRNA showed the strongest inhibition of Wnt3a-induced accumulation of β-catenin, whereas Fz2 and Fz4 siRNAs also had some inhibitory effect (Fig. S5A and Table SII). Combination of Fz2, 4, and 5 siRNAs virtually abolished Wnt3a-induced accumulation of β-catenin (Table SII). The combination also abrogated Wnt3a-induced formation of PtdIns (4,5)P2 (Fig. 3C) and phosphorylation of LRP6 at Ser1490 (Fig. 3D, Table SII, and Fig. S5, B and C). Expression of Fz5, Fz2 and Fz4 stimulated formation of PtdIns (4,5)P2 (Fig. 3E) and Wnt3a-induced phosphorylation of Ser1490 (Fig. (Fig.3F3F and S5, D and E). These results together indicate that Wnt3a acts through Fz to stimulate PtdIns (4,5)P2 formation in HEK293T cells and regulates LRP6 phosphorylation.

As Dvl is required for phosphorylation of LRP6 (9, 10), we questioned whether Dvl might have a role in formation of PtdIns (4,5)P2. Expression of Dvl1-3 increased the amount of PtdIns (4,5)P2 in HEK293T cells (Fig. (Fig.3G3G and S6A). When HEK293T cells were transfected with a mixture of three Dvl siRNAs targeting each of the three Dvl isoforms (16), both Wnt3a-induced formation of PtdIns (4,5)P2 and phosphorylation of Ser1490 were inhibited (Fig. 3, H and I and S6B). Dvl is a scaffold protein with no known enzymatic domains. Dvl and PIP5KIβ coimmunoprecipitated when they were overexpressed in HEK293T cells (Fig. S6C). We mapped Dvl interaction site to the N-terminal half of PIP5KIβ kinase domain (Fig. S6D) and PIP5KI-binding sites to two fragments of Dvl1 that contain the DIX and PDZ domain, respectively (Fig. S6E). The interaction of Dvl3 and PIP5KIβ was also examined in a HEK293T cell line that stably expressed Dvl3 carrying seven Hemagglutinin (HA) tags at its C-terminus at a level lower than that of endogenous Dvl3 (the right upper panel of Fig. 3J). Although we did not observe coimmunoprecipitation in the absence of Wnt3a, an interaction of Dvl3-HA with endogenous PIP5KIβ was detected in the presence of Wnt3a (Fig. 3J), suggesting that Wnt3a may regulate the interaction. In a pull-down assay with recombinant proteins prepared in E coli., Dvl1 interacted with PIP5KIβ and Iα in vitro (Fig. S6F). We then tested whether Dvl could directly regulate PIP5KI kinase activity. Using the recombinant Dvl3 and PIP5KIβ prepared from E coli., we found that, in an in vitro kinase assay, Dvl directly stimulated PIP5KIβ in a dose-dependent manner (Fig. (Fig.3K3K and S6G). All of the above data, together with the knowledge that Fz can interact with Dvl and recruit it to the membrane (9, 17-22), suggest that Wnt3a may induce, through Fz, Dvl to bind and activate PIP5KI.

We next tested whether PtdIns (4,5)P2 is required for Wnt3a-induced formation of LRP6 aggregates, referred to as “signalosomes”, which precedes phosphorylation of LRP6 at Thr1479 (9). We used sucrose density gradient centrifugation to detect LRP6 aggregates in cells treated with Wnt3a (Fig. 4A). Fractions that contained LRP6 aggregates also had a higher PtdIns (4,5)P2 content than those containing non-aggregated LRP6 (Fig. 4B). Importantly, the aggregation was sensitive to the elimination of PtdIns (4,5)P2 through rapamycin-induced PtdIns (4,5)P2 hydrolysis (Fig. 4A). We also examined LRP6 aggregation using confocal microscopy in Hela cells expressing LRP6-YFP (9). We observed the aggregates in control cells, but not in cells transfected with the PIP5KI siRNAs (Fig. S7). Elimination of PtdIns (4,5)P2 also led to decreased phosphorylation of Thr1479 (Fig. 4C) (9). Therefore, we conclude that PtdIns (4,5)P2 is required for Wnt-induced LRP6 aggregation and Thr1479 phosphorylation.

Figure 4
Requirement of PtdIns (4,5)P2 for formation of LRP6 aggregate and membrane translocation of Axin and GSK3

Because LRP6 aggregates appear to have a high affinity for Axin (9) and Axin membrane translocation is required for GSK3-mediated phosphorylation of Ser1490 (10), we examined if PtdIns (4,5)P2 is involved in Wnt-induced Axin membrane translocation. Elimination of PtdIns (4,5)P2 using the rapamycin-inducible system abrogated Wnt3a-idncued Axin translocation (Fig. 4D). Putting all these results together, we propose a model (Fig. 4E) that Wnt3a regulates the activity of PIP5KI via Fz and Dvl and induces the formation of PtdIns (4,5)P2. PtdIns (4,5)P2 is required, but not sufficient, for LRP6 aggregation and phosphorylation at Thr1479 and Ser1490 as well as Axin translocation. Precise mechanisms by which PtdIns (4,5)P2 regulates these events need to be further studied.

Supplementary Material

Acknowledgments

We thank Dr. De Camilli for making available resources from his lab in connection to this work, for discussion and for critical reading of the manuscript. We thank Zhong Li, Michelle Orsulak, Yazhou Zhang, Linling Tang, Wenzhong Liu, Ying Xi, Yizhong Wu, and Xiaoqing Gan for technical assistance, D. Sussman, C. Carpenter, R. Grosschedl, T. Balla, B. Williams, M.F. Roussel, X He, C. Niehrs, R. Nusse, and J. Nathans for providing experimental materials. This work is supported by grants from NIH (AR051476, CA132317, NS36251 and DA018343), and from NIDA to Yale Neuro-proteomics center.

REFERENCES

1. Logan CY, Nusse R. Annu Rev Cell Dev Biol. 2004;20:781. [PubMed]
2. Reya T, Clevers H. Nature. 2005 Apr 14;434:843. [PubMed]
3. Clevers H. Cell. 2006 Nov 3;127:469. [PubMed]
4. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. Nat Rev Genet. 2004 Sep;5:691. [PubMed]
5. Mani A, et al. Science. 2007 Mar 2;315:1278. [PMC free article] [PubMed]
6. Davidson G, et al. Nature. 2005 Dec 8;438:867. [PubMed]
7. Nusse R. Nature. 2005 Dec 8;438:747. [PubMed]
8. Zeng X, et al. Nature. 2005 Dec 8;438:873. [PMC free article] [PubMed]
9. Bilic J, et al. Science. 2007 Jun 15;316:1619. [PubMed]
10. Zeng X, et al. Development. 2007
11. Harland R, Gerhart J. Annu Rev Cell Dev Biol. 1997;13:611. [PubMed]
12. Hsuan JJ, Minogue S, dos Santos M. Adv Cancer Res. 1998;74:167. [PubMed]
13. Doughman RL, Firestone AJ, Anderson RA. The Journal of membrane biology. 2003 Jul 15;194:77. [PubMed]
14. Heo WD, et al. Science. 2006 Dec 1;314:1458. [PubMed]
15. Varnai P, Thyagarajan B, Rohacs T, Balla T. J Cell Biol. 2006 Nov 6;175:377. [PMC free article] [PubMed]
16. Li L, Mao J, Sun L, Liu W, Wu D. J Biol Chem. 2002;277:5977. [PubMed]
17. Axelrod JD, Miller JR, Shulman JM, Moon RT, Perrimon N. Genes Dev. 1998;12:2610. [PubMed]
18. Wong HC, et al. Mol. Cell. 2003 Nov;12:1251. [PubMed]
19. Chen W, et al. Science. 2003;301:1391. [PubMed]
20. Cong F, Schweizer L, Varmus H. Development. 2004 Oct;131:5103. [PubMed]
21. Pan WJ, et al. Cell Res. 2004 Aug;14:324. [PubMed]
22. Yokoyama N, Yin D, Malbon CC. J Mol Signal. 2007;2:11. [PMC free article] [PubMed]